-
Je něco špatně v tomto záznamu ?
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer
F. Wang, X. Yu, X. Shen, G. Zhu, Y. Huang, R. Liu, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, AK. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, CJ. O'Neill, MS. Sywak, R....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie
Grantová podpora
NV16-32665A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Free Medical Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2017-01-01 do 2020-12-31
Health & Medicine (ProQuest)
od 2017-01-01 do 2020-12-31
PubMed
28582521
DOI
10.1210/jc.2017-00277
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- invazivní růst nádoru patologie MeSH
- Kaplanův-Meierův odhad MeSH
- karcinom mortalita patologie chirurgie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru mortalita patologie MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny patologie MeSH
- míra přežití MeSH
- multivariační analýza MeSH
- nádory štítné žlázy mortalita patologie chirurgie MeSH
- papilární karcinom mortalita patologie chirurgie MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- program SEER MeSH
- proporcionální rizikové modely MeSH
- staging nádorů MeSH
- tyreoidektomie metody mortalita MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- srovnávací studie MeSH
Context: Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC), prompting aggressive treatments, but its prognostic value remains unestablished. Objective: To investigate the role of tumor multifocality in clinical outcomes of PTC. Methods: Multicenter study of the relationship between multifocality and clinical outcomes of PTC in 2638 patients (623 men and 2015 women) with median [interquartile range (IQR)] age of 46 (35 to 58) years and median (IQR) follow-up time of 58 (26 to 107) months at 11 medical centers in six countries. Surveillance, Epidemiology and End Results (SEER) data were used for validation. Results: Disease recurrence in multifocal and unifocal PTC was 198 of 1000 (19.8%) and 221 of 1624 (13.6%) (P < 0.001), with a hazard ratio of 1.55 [95% confidence interval (CI), 1.28 to 1.88], which became insignificant at 1.13 (95% CI, 0.93 to 1.37) on multivariate adjustment. Similar results were obtained in PTC variants: conventional PTC, follicular-variant PTC, tall-cell PTC, and papillary thyroid microcarcinoma. There was no association between multifocality and mortality in any of these PTC settings, whereas there was a strong association between classic risk factors and cancer recurrence or mortality, which remained significant after multivariate adjustment. In 1423 patients with intrathyroidal PTC, disease recurrence was 20 of 455 (4.4%) and 41 of 967 (4.2%) (P = 0.892) and mortality was 0 of 455 (0.0%) and 3 of 967 (0.3%) (P = 0.556) in multifocal and unifocal PTC, respectively. The results were reproduced in 89,680 patients with PTC in the SEER database. Conclusions: Tumor multifocality has no independent risk prognostic value in clinical outcomes of PTC; its indiscriminate use as an independent risk factor, prompting overtreatments of patients, should be avoided.
Department of Endocrinology and Metabolism Shandong Provincial Hospital Jinan 250021 China
Department of Internal Medicine University of Perugia 06100 Perugia Italy
Department of Medicine Endocrinology Unit University of Padua Padua 35128 Italy
Department of Molecular Endocrinology Institute of Endocrinology Prague 11694 Czech Republic
Endocrine Surgical Unit The University of Sydney Sydney 2052 Australia
Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology 44 101 Gliwice Poland
Prenatal Diagnosis Center The Affiliated Hospital of Qingdao University Qingdao 266003 China
Veneto Institute of Oncology Instituto di Ricovero e Cura a Carattere Scientifico Padua 35128 Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016569
- 003
- CZ-PrNML
- 005
- 20180523130437.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1210/jc.2017-00277 $2 doi
- 035 __
- $a (PubMed)28582521
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wang, Fei $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287. Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
- 245 14
- $a The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer / $c F. Wang, X. Yu, X. Shen, G. Zhu, Y. Huang, R. Liu, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, AK. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, CJ. O'Neill, MS. Sywak, R. Clifton-Bligh, B. Bendlova, V. Sýkorová, Y. Wang, S. Liu, J. Zhao, S. Zhao, M. Xing,
- 520 9_
- $a Context: Multifocality is often treated as a risk factor for papillary thyroid cancer (PTC), prompting aggressive treatments, but its prognostic value remains unestablished. Objective: To investigate the role of tumor multifocality in clinical outcomes of PTC. Methods: Multicenter study of the relationship between multifocality and clinical outcomes of PTC in 2638 patients (623 men and 2015 women) with median [interquartile range (IQR)] age of 46 (35 to 58) years and median (IQR) follow-up time of 58 (26 to 107) months at 11 medical centers in six countries. Surveillance, Epidemiology and End Results (SEER) data were used for validation. Results: Disease recurrence in multifocal and unifocal PTC was 198 of 1000 (19.8%) and 221 of 1624 (13.6%) (P < 0.001), with a hazard ratio of 1.55 [95% confidence interval (CI), 1.28 to 1.88], which became insignificant at 1.13 (95% CI, 0.93 to 1.37) on multivariate adjustment. Similar results were obtained in PTC variants: conventional PTC, follicular-variant PTC, tall-cell PTC, and papillary thyroid microcarcinoma. There was no association between multifocality and mortality in any of these PTC settings, whereas there was a strong association between classic risk factors and cancer recurrence or mortality, which remained significant after multivariate adjustment. In 1423 patients with intrathyroidal PTC, disease recurrence was 20 of 455 (4.4%) and 41 of 967 (4.2%) (P = 0.892) and mortality was 0 of 455 (0.0%) and 3 of 967 (0.3%) (P = 0.556) in multifocal and unifocal PTC, respectively. The results were reproduced in 89,680 patients with PTC in the SEER database. Conclusions: Tumor multifocality has no independent risk prognostic value in clinical outcomes of PTC; its indiscriminate use as an independent risk factor, prompting overtreatments of patients, should be avoided.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a karcinom $x mortalita $x patologie $x chirurgie $7 D002277
- 650 _2
- $a papilární karcinom $x mortalita $x patologie $x chirurgie $7 D002291
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a lymfatické uzliny $x patologie $7 D008198
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a invazivní růst nádoru $x patologie $7 D009361
- 650 _2
- $a lokální recidiva nádoru $x mortalita $x patologie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a program SEER $7 D018426
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a nádory štítné žlázy $x mortalita $x patologie $x chirurgie $7 D013964
- 650 _2
- $a tyreoidektomie $x metody $x mortalita $7 D013965
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Yu, Xiaolong $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287. Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
- 700 1_
- $a Shen, Xiaopei $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
- 700 1_
- $a Zhu, Guangwu $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
- 700 1_
- $a Huang, Yueye $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
- 700 1_
- $a Liu, Rengyun $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
- 700 1_
- $a Viola, David $u Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa School of Medicine, 56124 Pisa, Italy.
- 700 1_
- $a Elisei, Rossella $u Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa School of Medicine, 56124 Pisa, Italy.
- 700 1_
- $a Puxeddu, Efisio $u Department of Internal Medicine, University of Perugia, 06100 Perugia, Italy.
- 700 1_
- $a Fugazzola, Laura $u Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano and Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
- 700 1_
- $a Colombo, Carla $u Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano and Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
- 700 1_
- $a Jarzab, Barbara $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 44-101 Gliwice, Poland.
- 700 1_
- $a Czarniecka, Agnieszka $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 44-101 Gliwice, Poland.
- 700 1_
- $a Lam, Alfred K $u Cancer Molecular Pathology of School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast 4222, Australia.
- 700 1_
- $a Mian, Caterina $u Department of Medicine, Endocrinology Unit, University of Padua, Padua 35128, Italy.
- 700 1_
- $a Vianello, Federica $u Veneto Institute of Oncology, Instituto di Ricovero e Cura a Carattere Scientifico, Padua 35128, Italy.
- 700 1_
- $a Yip, Linwah $u Department of Surgery, Division of Endocrine Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213.
- 700 1_
- $a Riesco-Eizaguirre, Garcilaso $u Department of Endocrinology and Nutrition, Hospital La Paz, Health Research Institute, and Hospital Universitario de Móstoles, Department of Endocrinology, Hospital Universitario de Móstoles, 28029 Madrid, Spain. Biomedical Research Institute, "Alberto Sols," Spanish Council of Research Consejo Superior de Investigaciones Científicas and Autonomous University of Madrid, 28029 Madrid, Spain.
- 700 1_
- $a Santisteban, Pilar $u Biomedical Research Institute, "Alberto Sols," Spanish Council of Research Consejo Superior de Investigaciones Científicas and Autonomous University of Madrid, 28029 Madrid, Spain.
- 700 1_
- $a O'Neill, Christine J $u Endocrine Surgical Unit, The University of Sydney, Sydney 2052, Australia.
- 700 1_
- $a Sywak, Mark S $u Endocrine Surgical Unit, The University of Sydney, Sydney 2052, Australia.
- 700 1_
- $a Clifton-Bligh, Roderick $u Endocrine Surgical Unit, The University of Sydney, Sydney 2052, Australia.
- 700 1_
- $a Bendlova, Bela $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 11694, Czech Republic.
- 700 1_
- $a Sýkorová, Vlasta $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague 11694, Czech Republic.
- 700 1_
- $a Wang, Yangang $u Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
- 700 1_
- $a Liu, Shiguo $u Prenatal Diagnosis Center, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
- 700 1_
- $a Zhao, Jiajun $u Department of Endocrinology and Metabolism, Shandong Provincial Hospital, Jinan 250021, China.
- 700 1_
- $a Zhao, Shihua $u Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
- 700 1_
- $a Xing, Mingzhao $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287.
- 773 0_
- $w MED00002582 $t The Journal of clinical endocrinology and metabolism $x 1945-7197 $g Roč. 102, č. 9 (2017), s. 3241-3250
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28582521 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180523130621 $b ABA008
- 999 __
- $a ok $b bmc $g 1300193 $s 1013409
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 102 $c 9 $d 3241-3250 $i 1945-7197 $m The Journal of clinical endocrinology and metabolism $n J Clin Endocrinol Metab $x MED00002582
- GRA __
- $a NV16-32665A $p MZ0
- LZP __
- $a Pubmed-20180515
